IBDEI00P ; ; 01-AUG-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,1136,1,3,0)
;;=3^Chronic myeloid leuk, BCR/ABL-positive, not achieve remis
;;^UTILITY(U,$J,358.3,1136,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,1136,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,1137,0)
;;=C92.11^^10^77^29
;;^UTILITY(U,$J,358.3,1137,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1137,1,3,0)
;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
;;^UTILITY(U,$J,358.3,1137,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,1137,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,1138,0)
;;=C92.12^^10^77^30
;;^UTILITY(U,$J,358.3,1138,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1138,1,3,0)
;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
;;^UTILITY(U,$J,358.3,1138,1,4,0)
;;=4^C92.12
;;^UTILITY(U,$J,358.3,1138,2)
;;=^5001794
;;^UTILITY(U,$J,358.3,1139,0)
;;=C92.20^^10^77^22
;;^UTILITY(U,$J,358.3,1139,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1139,1,3,0)
;;=3^Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
;;^UTILITY(U,$J,358.3,1139,1,4,0)
;;=4^C92.20
;;^UTILITY(U,$J,358.3,1139,2)
;;=^5001795
;;^UTILITY(U,$J,358.3,1140,0)
;;=C92.21^^10^77^23
;;^UTILITY(U,$J,358.3,1140,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1140,1,3,0)
;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
;;^UTILITY(U,$J,358.3,1140,1,4,0)
;;=4^C92.21
;;^UTILITY(U,$J,358.3,1140,2)
;;=^5001796
;;^UTILITY(U,$J,358.3,1141,0)
;;=C92.22^^10^77^24
;;^UTILITY(U,$J,358.3,1141,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1141,1,3,0)
;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
;;^UTILITY(U,$J,358.3,1141,1,4,0)
;;=4^C92.22
;;^UTILITY(U,$J,358.3,1141,2)
;;=^5001797
;;^UTILITY(U,$J,358.3,1142,0)
;;=C92.30^^10^77^57
;;^UTILITY(U,$J,358.3,1142,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1142,1,3,0)
;;=3^Myeloid sarcoma, not having achieved remission
;;^UTILITY(U,$J,358.3,1142,1,4,0)
;;=4^C92.30
;;^UTILITY(U,$J,358.3,1142,2)
;;=^5001798
;;^UTILITY(U,$J,358.3,1143,0)
;;=C92.31^^10^77^56
;;^UTILITY(U,$J,358.3,1143,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1143,1,3,0)
;;=3^Myeloid sarcoma, in remission
;;^UTILITY(U,$J,358.3,1143,1,4,0)
;;=4^C92.31
;;^UTILITY(U,$J,358.3,1143,2)
;;=^5001799
;;^UTILITY(U,$J,358.3,1144,0)
;;=C92.32^^10^77^55
;;^UTILITY(U,$J,358.3,1144,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1144,1,3,0)
;;=3^Myeloid sarcoma, in relapse
;;^UTILITY(U,$J,358.3,1144,1,4,0)
;;=4^C92.32
;;^UTILITY(U,$J,358.3,1144,2)
;;=^5001800
;;^UTILITY(U,$J,358.3,1145,0)
;;=C92.90^^10^77^54
;;^UTILITY(U,$J,358.3,1145,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1145,1,3,0)
;;=3^Myeloid leukemia, unspecified, not having achieved remission
;;^UTILITY(U,$J,358.3,1145,1,4,0)
;;=4^C92.90
;;^UTILITY(U,$J,358.3,1145,2)
;;=^5001810
;;^UTILITY(U,$J,358.3,1146,0)
;;=C92.91^^10^77^53
;;^UTILITY(U,$J,358.3,1146,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1146,1,3,0)
;;=3^Myeloid leukemia, unspecified in remission
;;^UTILITY(U,$J,358.3,1146,1,4,0)
;;=4^C92.91
;;^UTILITY(U,$J,358.3,1146,2)
;;=^5001811
;;^UTILITY(U,$J,358.3,1147,0)
;;=C92.92^^10^77^52
;;^UTILITY(U,$J,358.3,1147,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1147,1,3,0)
;;=3^Myeloid leukemia, unspecified in relapse
;;^UTILITY(U,$J,358.3,1147,1,4,0)
;;=4^C92.92
;;^UTILITY(U,$J,358.3,1147,2)
;;=^5001812
;;^UTILITY(U,$J,358.3,1148,0)
;;=C93.00^^10^77^12
;;^UTILITY(U,$J,358.3,1148,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1148,1,3,0)
;;=3^Acute monoblastic/monocytic leukemia, not achieve remission
;;^UTILITY(U,$J,358.3,1148,1,4,0)
;;=4^C93.00
;;^UTILITY(U,$J,358.3,1148,2)
;;=^5001819
;;^UTILITY(U,$J,358.3,1149,0)
;;=C93.01^^10^77^10
;;^UTILITY(U,$J,358.3,1149,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1149,1,3,0)
;;=3^Acute monoblastic/monocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,1149,1,4,0)
;;=4^C93.01
;;^UTILITY(U,$J,358.3,1149,2)
;;=^5001820
;;^UTILITY(U,$J,358.3,1150,0)
;;=C93.02^^10^77^11
;;^UTILITY(U,$J,358.3,1150,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1150,1,3,0)
;;=3^Acute monoblastic/monocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,1150,1,4,0)
;;=4^C93.02
;;^UTILITY(U,$J,358.3,1150,2)
;;=^5001821
;;^UTILITY(U,$J,358.3,1151,0)
;;=C93.10^^10^77^31
;;^UTILITY(U,$J,358.3,1151,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1151,1,3,0)
;;=3^Chronic myelomonocytic leukemia not achieve remission
;;^UTILITY(U,$J,358.3,1151,1,4,0)
;;=4^C93.10
;;^UTILITY(U,$J,358.3,1151,2)
;;=^5001822
;;^UTILITY(U,$J,358.3,1152,0)
;;=C93.11^^10^77^33
;;^UTILITY(U,$J,358.3,1152,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1152,1,3,0)
;;=3^Chronic myelomonocytic leukemia, in remission
;;^UTILITY(U,$J,358.3,1152,1,4,0)
;;=4^C93.11
;;^UTILITY(U,$J,358.3,1152,2)
;;=^5001823
;;^UTILITY(U,$J,358.3,1153,0)
;;=C93.12^^10^77^32
;;^UTILITY(U,$J,358.3,1153,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1153,1,3,0)
;;=3^Chronic myelomonocytic leukemia, in relapse
;;^UTILITY(U,$J,358.3,1153,1,4,0)
;;=4^C93.12
;;^UTILITY(U,$J,358.3,1153,2)
;;=^5001824
;;^UTILITY(U,$J,358.3,1154,0)
;;=C93.90^^10^77^48
;;^UTILITY(U,$J,358.3,1154,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1154,1,3,0)
;;=3^Monocytic leukemia, unsp, not having achieved remission
;;^UTILITY(U,$J,358.3,1154,1,4,0)
;;=4^C93.90
;;^UTILITY(U,$J,358.3,1154,2)
;;=^5001828
;;^UTILITY(U,$J,358.3,1155,0)
;;=C93.91^^10^77^50
;;^UTILITY(U,$J,358.3,1155,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1155,1,3,0)
;;=3^Monocytic leukemia, unspecified in remission
;;^UTILITY(U,$J,358.3,1155,1,4,0)
;;=4^C93.91
;;^UTILITY(U,$J,358.3,1155,2)
;;=^5001829
;;^UTILITY(U,$J,358.3,1156,0)
;;=C93.92^^10^77^49
;;^UTILITY(U,$J,358.3,1156,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1156,1,3,0)
;;=3^Monocytic leukemia, unspecified in relapse
;;^UTILITY(U,$J,358.3,1156,1,4,0)
;;=4^C93.92
;;^UTILITY(U,$J,358.3,1156,2)
;;=^5001830
;;^UTILITY(U,$J,358.3,1157,0)
;;=C94.00^^10^77^3
;;^UTILITY(U,$J,358.3,1157,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1157,1,3,0)
;;=3^Acute erythroid leukemia, not having achieved remission
;;^UTILITY(U,$J,358.3,1157,1,4,0)
;;=4^C94.00
;;^UTILITY(U,$J,358.3,1157,2)
;;=^5001834
;;^UTILITY(U,$J,358.3,1158,0)
;;=C94.01^^10^77^2
;;^UTILITY(U,$J,358.3,1158,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1158,1,3,0)
;;=3^Acute erythroid leukemia, in remission
;;^UTILITY(U,$J,358.3,1158,1,4,0)
;;=4^C94.01
;;^UTILITY(U,$J,358.3,1158,2)
;;=^5001835
;;^UTILITY(U,$J,358.3,1159,0)
;;=C94.02^^10^77^1
;;^UTILITY(U,$J,358.3,1159,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1159,1,3,0)
;;=3^Acute erythroid leukemia, in relapse
;;^UTILITY(U,$J,358.3,1159,1,4,0)
;;=4^C94.02
;;^UTILITY(U,$J,358.3,1159,2)
;;=^5001836
;;^UTILITY(U,$J,358.3,1160,0)
;;=C94.20^^10^77^7
;;^UTILITY(U,$J,358.3,1160,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1160,1,3,0)
;;=3^Acute megakaryoblastic leukemia not achieve remission
;;^UTILITY(U,$J,358.3,1160,1,4,0)
;;=4^C94.20
;;^UTILITY(U,$J,358.3,1160,2)
;;=^5001837
;;^UTILITY(U,$J,358.3,1161,0)
;;=C94.21^^10^77^9
;;^UTILITY(U,$J,358.3,1161,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1161,1,3,0)
;;=3^Acute megakaryoblastic leukemia, in remission
;;^UTILITY(U,$J,358.3,1161,1,4,0)
;;=4^C94.21
;;^UTILITY(U,$J,358.3,1161,2)
;;=^5001838
;;^UTILITY(U,$J,358.3,1162,0)
;;=C94.22^^10^77^8
;;^UTILITY(U,$J,358.3,1162,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1162,1,3,0)
;;=3^Acute megakaryoblastic leukemia, in relapse
;;^UTILITY(U,$J,358.3,1162,1,4,0)
;;=4^C94.22
;;^UTILITY(U,$J,358.3,1162,2)
;;=^5001839
;;^UTILITY(U,$J,358.3,1163,0)
;;=C94.30^^10^77^45
;;^UTILITY(U,$J,358.3,1163,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1163,1,3,0)
;;=3^Mast cell leukemia not having achieved remission
;;^UTILITY(U,$J,358.3,1163,1,4,0)
;;=4^C94.30
;;^UTILITY(U,$J,358.3,1163,2)
;;=^5001840
;;^UTILITY(U,$J,358.3,1164,0)
;;=C94.31^^10^77^47
;;^UTILITY(U,$J,358.3,1164,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1164,1,3,0)
;;=3^Mast cell leukemia, in remission
;;^UTILITY(U,$J,358.3,1164,1,4,0)
;;=4^C94.31
;;^UTILITY(U,$J,358.3,1164,2)
;;=^5001841
;;^UTILITY(U,$J,358.3,1165,0)
;;=C94.32^^10^77^46
;;^UTILITY(U,$J,358.3,1165,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1165,1,3,0)
;;=3^Mast cell leukemia, in relapse
;;^UTILITY(U,$J,358.3,1165,1,4,0)
;;=4^C94.32
;;^UTILITY(U,$J,358.3,1165,2)
;;=^5001842
;;^UTILITY(U,$J,358.3,1166,0)
;;=C95.00^^10^77^4
;;^UTILITY(U,$J,358.3,1166,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1166,1,3,0)
;;=3^Acute leukemia of unsp cell type not achieve remission
;;^UTILITY(U,$J,358.3,1166,1,4,0)
;;=4^C95.00
;;^UTILITY(U,$J,358.3,1166,2)
;;=^5001850
;;^UTILITY(U,$J,358.3,1167,0)
;;=C95.01^^10^77^5
;;^UTILITY(U,$J,358.3,1167,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1167,1,3,0)
;;=3^Acute leukemia of unspecified cell type, in remission
;;^UTILITY(U,$J,358.3,1167,1,4,0)
;;=4^C95.01
;;^UTILITY(U,$J,358.3,1167,2)
;;=^5001851
;;^UTILITY(U,$J,358.3,1168,0)
;;=C95.02^^10^77^6
;;^UTILITY(U,$J,358.3,1168,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1168,1,3,0)
;;=3^Acute leukemia of unspecified cell type, in relapse
;;^UTILITY(U,$J,358.3,1168,1,4,0)
;;=4^C95.02
;;^UTILITY(U,$J,358.3,1168,2)
;;=^5001852
;;^UTILITY(U,$J,358.3,1169,0)
;;=D45.^^10^77^58
;;^UTILITY(U,$J,358.3,1169,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1169,1,3,0)
;;=3^Polycythemia vera
;;^UTILITY(U,$J,358.3,1169,1,4,0)
;;=4^D45.
;;^UTILITY(U,$J,358.3,1169,2)
;;=^96105
;;^UTILITY(U,$J,358.3,1170,0)
;;=C95.10^^10^77^25
;;^UTILITY(U,$J,358.3,1170,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1170,1,3,0)
;;=3^Chronic leukemia of unsp cell type not achieve remission
;;^UTILITY(U,$J,358.3,1170,1,4,0)
;;=4^C95.10
;;^UTILITY(U,$J,358.3,1170,2)
;;=^5001853
;;^UTILITY(U,$J,358.3,1171,0)
;;=C95.11^^10^77^26
;;^UTILITY(U,$J,358.3,1171,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1171,1,3,0)
;;=3^Chronic leukemia of unspecified cell type, in remission
;;^UTILITY(U,$J,358.3,1171,1,4,0)
;;=4^C95.11
;;^UTILITY(U,$J,358.3,1171,2)
;;=^5001854
;;^UTILITY(U,$J,358.3,1172,0)
;;=C95.12^^10^77^27
;;^UTILITY(U,$J,358.3,1172,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1172,1,3,0)
;;=3^Chronic leukemia of unspecified cell type, in relapse
;;^UTILITY(U,$J,358.3,1172,1,4,0)
;;=4^C95.12
;;^UTILITY(U,$J,358.3,1172,2)
;;=^5001855
;;^UTILITY(U,$J,358.3,1173,0)
;;=D46.9^^10^77^51
;;^UTILITY(U,$J,358.3,1173,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1173,1,3,0)
;;=3^Myelodysplastic syndrome, unspecified
;;^UTILITY(U,$J,358.3,1173,1,4,0)
;;=4^D46.9
;;^UTILITY(U,$J,358.3,1173,2)
;;=^334031
;;^UTILITY(U,$J,358.3,1174,0)
;;=C95.90^^10^77^39
;;^UTILITY(U,$J,358.3,1174,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1174,1,3,0)
;;=3^Leukemia, unspecified not having achieved remission
;;^UTILITY(U,$J,358.3,1174,1,4,0)
;;=4^C95.90
;;^UTILITY(U,$J,358.3,1174,2)
;;=^5001856
;;^UTILITY(U,$J,358.3,1175,0)
;;=C95.91^^10^77^41
;;^UTILITY(U,$J,358.3,1175,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1175,1,3,0)
;;=3^Leukemia, unspecified, in remission
;;^UTILITY(U,$J,358.3,1175,1,4,0)
;;=4^C95.91
;;^UTILITY(U,$J,358.3,1175,2)
;;=^5001857
;;^UTILITY(U,$J,358.3,1176,0)
;;=C95.92^^10^77^40
;;^UTILITY(U,$J,358.3,1176,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1176,1,3,0)
;;=3^Leukemia, unspecified, in relapse
;;^UTILITY(U,$J,358.3,1176,1,4,0)
;;=4^C95.92
;;^UTILITY(U,$J,358.3,1176,2)
;;=^5001858
;;^UTILITY(U,$J,358.3,1177,0)
;;=D72.9^^10^77^35
;;^UTILITY(U,$J,358.3,1177,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1177,1,3,0)
;;=3^Disorder of white blood cells, unspecified
;;^UTILITY(U,$J,358.3,1177,1,4,0)
;;=4^D72.9
;;^UTILITY(U,$J,358.3,1177,2)
;;=^5002381
;;^UTILITY(U,$J,358.3,1178,0)
;;=D75.1^^10^77^59
;;^UTILITY(U,$J,358.3,1178,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1178,1,3,0)
;;=3^Secondary polycythemia
;;^UTILITY(U,$J,358.3,1178,1,4,0)
;;=4^D75.1
;;^UTILITY(U,$J,358.3,1178,2)
;;=^186856
;;^UTILITY(U,$J,358.3,1179,0)
;;=D75.9^^10^77^34
;;^UTILITY(U,$J,358.3,1179,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1179,1,3,0)
;;=3^Disease of blood and blood-forming organs, unspecified
;;^UTILITY(U,$J,358.3,1179,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,1179,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,1180,0)
;;=C7A.010^^10^77^42
;;^UTILITY(U,$J,358.3,1180,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1180,1,3,0)
;;=3^Malignant carcinoid tumor of the duodenum
;;^UTILITY(U,$J,358.3,1180,1,4,0)
;;=4^C7A.010
;;^UTILITY(U,$J,358.3,1180,2)
;;=^5001359
;;^UTILITY(U,$J,358.3,1181,0)
;;=C7A.011^^10^77^44
;;^UTILITY(U,$J,358.3,1181,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1181,1,3,0)
;;=3^Malignant carcinoid tumor of the jejunum
;;^UTILITY(U,$J,358.3,1181,1,4,0)
;;=4^C7A.011
;;^UTILITY(U,$J,358.3,1181,2)
;;=^5001360
;;^UTILITY(U,$J,358.3,1182,0)
;;=C7A.012^^10^77^43
;;^UTILITY(U,$J,358.3,1182,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1182,1,3,0)
;;=3^Malignant carcinoid tumor of the ileum
;;^UTILITY(U,$J,358.3,1182,1,4,0)
;;=4^C7A.012
;;^UTILITY(U,$J,358.3,1182,2)
;;=^5001361
;;^UTILITY(U,$J,358.3,1183,0)
;;=C93.30^^10^77^38
;;^UTILITY(U,$J,358.3,1183,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1183,1,3,0)
;;=3^Juvenile myelomonocytic leukemia,no remission
;;^UTILITY(U,$J,358.3,1183,1,4,0)
;;=4^C93.30
;;^UTILITY(U,$J,358.3,1183,2)
;;=^5001825
;;^UTILITY(U,$J,358.3,1184,0)
;;=C93.31^^10^77^37
;;^UTILITY(U,$J,358.3,1184,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1184,1,3,0)
;;=3^Juvenile myelomonocytic leukemia,in remission
;;^UTILITY(U,$J,358.3,1184,1,4,0)
;;=4^C93.31
;;^UTILITY(U,$J,358.3,1184,2)
;;=^5001826
;;^UTILITY(U,$J,358.3,1185,0)
;;=C93.32^^10^77^36
;;^UTILITY(U,$J,358.3,1185,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1185,1,3,0)
;;=3^Juvenile myelomonocytic leukemia,in relapse
;;^UTILITY(U,$J,358.3,1185,1,4,0)
;;=4^C93.32
;;^UTILITY(U,$J,358.3,1185,2)
;;=^5001827
;;^UTILITY(U,$J,358.3,1186,0)
;;=D48.0^^10^78^5
;;^UTILITY(U,$J,358.3,1186,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1186,1,3,0)
;;=3^Neoplasm of uncertain behavior of bone/artic cartl
;;^UTILITY(U,$J,358.3,1186,1,4,0)
;;=4^D48.0
;;^UTILITY(U,$J,358.3,1186,2)
;;=^81953
;;^UTILITY(U,$J,358.3,1187,0)
;;=D48.1^^10^78^6
;;^UTILITY(U,$J,358.3,1187,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1187,1,3,0)
;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
;;^UTILITY(U,$J,358.3,1187,1,4,0)
;;=4^D48.1
;;^UTILITY(U,$J,358.3,1187,2)
;;=^267776
;;^UTILITY(U,$J,358.3,1188,0)
;;=D48.5^^10^78^10
;;^UTILITY(U,$J,358.3,1188,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1188,1,3,0)
;;=3^Neoplasm of uncertain behavior of skin
;;^UTILITY(U,$J,358.3,1188,1,4,0)
;;=4^D48.5
;;^UTILITY(U,$J,358.3,1188,2)
;;=^267777
;;^UTILITY(U,$J,358.3,1189,0)
;;=D48.61^^10^78^9
;;^UTILITY(U,$J,358.3,1189,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1189,1,3,0)
;;=3^Neoplasm of uncertain behavior of right breast
;;^UTILITY(U,$J,358.3,1189,1,4,0)
;;=4^D48.61
;;^UTILITY(U,$J,358.3,1189,2)
;;=^5002267
;;^UTILITY(U,$J,358.3,1190,0)
;;=D48.62^^10^78^7
;;^UTILITY(U,$J,358.3,1190,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1190,1,3,0)
;;=3^Neoplasm of uncertain behavior of left breast
;;^UTILITY(U,$J,358.3,1190,1,4,0)
;;=4^D48.62
;;^UTILITY(U,$J,358.3,1190,2)
;;=^5002268
;;^UTILITY(U,$J,358.3,1191,0)
;;=D46.0^^10^78^18
;;^UTILITY(U,$J,358.3,1191,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1191,1,3,0)
;;=3^Refractory anemia without ring sideroblasts, so stated
;;^UTILITY(U,$J,358.3,1191,1,4,0)
;;=4^D46.0
;;^UTILITY(U,$J,358.3,1191,2)
;;=^5002245
;;^UTILITY(U,$J,358.3,1192,0)
;;=D46.1^^10^78^17
;;^UTILITY(U,$J,358.3,1192,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1192,1,3,0)
;;=3^Refractory anemia with ring sideroblasts
;;^UTILITY(U,$J,358.3,1192,1,4,0)
;;=4^D46.1
;;^UTILITY(U,$J,358.3,1192,2)
;;=^5002246
;;^UTILITY(U,$J,358.3,1193,0)
;;=D46.20^^10^78^14
;;^UTILITY(U,$J,358.3,1193,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1193,1,3,0)
;;=3^Refractory anemia with excess of blasts, unspecified
;;^UTILITY(U,$J,358.3,1193,1,4,0)
;;=4^D46.20
;;^UTILITY(U,$J,358.3,1193,2)
;;=^5002247
;;^UTILITY(U,$J,358.3,1194,0)
;;=D46.21^^10^78^15
;;^UTILITY(U,$J,358.3,1194,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1194,1,3,0)
;;=3^Refractory anemia with excess of blasts 1
;;^UTILITY(U,$J,358.3,1194,1,4,0)
;;=4^D46.21
;;^UTILITY(U,$J,358.3,1194,2)
;;=^5002248
;;^UTILITY(U,$J,358.3,1195,0)
;;=D46.A^^10^78^19
;;^UTILITY(U,$J,358.3,1195,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1195,1,3,0)
;;=3^Refractory cytopenia with multilineage dysplasia
;;^UTILITY(U,$J,358.3,1195,1,4,0)
;;=4^D46.A
;;^UTILITY(U,$J,358.3,1195,2)
;;=^5002251
;;^UTILITY(U,$J,358.3,1196,0)
;;=D46.B^^10^78^13
;;^UTILITY(U,$J,358.3,1196,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1196,1,3,0)
;;=3^Refract cytopenia w multilin dysplasia and ring sideroblasts
;;^UTILITY(U,$J,358.3,1196,1,4,0)
;;=4^D46.B
;;^UTILITY(U,$J,358.3,1196,2)
;;=^5002252
;;^UTILITY(U,$J,358.3,1197,0)
;;=D46.22^^10^78^16
;;^UTILITY(U,$J,358.3,1197,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1197,1,3,0)
;;=3^Refractory anemia with excess of blasts 2
;;^UTILITY(U,$J,358.3,1197,1,4,0)
;;=4^D46.22
;;^UTILITY(U,$J,358.3,1197,2)
;;=^5002249
;;^UTILITY(U,$J,358.3,1198,0)
;;=D46.C^^10^78^3
;;^UTILITY(U,$J,358.3,1198,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1198,1,3,0)
;;=3^Myelodysplastic syndrome w isolated del(5q) chromsoml abnlt
;;^UTILITY(U,$J,358.3,1198,1,4,0)
;;=4^D46.C
;;^UTILITY(U,$J,358.3,1198,2)
;;=^5002253
;;^UTILITY(U,$J,358.3,1199,0)
;;=D46.9^^10^78^4
;;^UTILITY(U,$J,358.3,1199,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1199,1,3,0)
;;=3^Myelodysplastic syndrome, unspecified
;;^UTILITY(U,$J,358.3,1199,1,4,0)
;;=4^D46.9
;;^UTILITY(U,$J,358.3,1199,2)
;;=^334031
;;^UTILITY(U,$J,358.3,1200,0)
;;=D47.1^^10^78^1
;;^UTILITY(U,$J,358.3,1200,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1200,1,3,0)
;;=3^Chronic myeloproliferative disease
;;^UTILITY(U,$J,358.3,1200,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,1200,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,1201,0)
;;=D47.Z1^^10^78^12
;;^UTILITY(U,$J,358.3,1201,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1201,1,3,0)
;;=3^Post-transplant lymphoproliferative disorder (PTLD)
;;^UTILITY(U,$J,358.3,1201,1,4,0)
;;=4^D47.Z1
;;^UTILITY(U,$J,358.3,1201,2)
;;=^5002261
;;^UTILITY(U,$J,358.3,1202,0)
;;=D48.7^^10^78^8
;;^UTILITY(U,$J,358.3,1202,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,1202,1,3,0)
;;=3^Neoplasm of uncertain behavior of other specified sites
;;^UTILITY(U,$J,358.3,1202,1,4,0)
;;=4^D48.7
;;^UTILITY(U,$J,358.3,1202,2)
;;=^267779
;;^UTILITY(U,$J,358.3,1203,0)
;;=D48.9^^10^78^11
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI00P 19768 printed Sep 23, 2025@19:15:18 Page 2
IBDEI00P ; ; 01-AUG-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,1136,1,3,0)
+2 ;;=3^Chronic myeloid leuk, BCR/ABL-positive, not achieve remis
+3 ;;^UTILITY(U,$J,358.3,1136,1,4,0)
+4 ;;=4^C92.10
+5 ;;^UTILITY(U,$J,358.3,1136,2)
+6 ;;=^5001792
+7 ;;^UTILITY(U,$J,358.3,1137,0)
+8 ;;=C92.11^^10^77^29
+9 ;;^UTILITY(U,$J,358.3,1137,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,1137,1,3,0)
+12 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
+13 ;;^UTILITY(U,$J,358.3,1137,1,4,0)
+14 ;;=4^C92.11
+15 ;;^UTILITY(U,$J,358.3,1137,2)
+16 ;;=^5001793
+17 ;;^UTILITY(U,$J,358.3,1138,0)
+18 ;;=C92.12^^10^77^30
+19 ;;^UTILITY(U,$J,358.3,1138,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,1138,1,3,0)
+22 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
+23 ;;^UTILITY(U,$J,358.3,1138,1,4,0)
+24 ;;=4^C92.12
+25 ;;^UTILITY(U,$J,358.3,1138,2)
+26 ;;=^5001794
+27 ;;^UTILITY(U,$J,358.3,1139,0)
+28 ;;=C92.20^^10^77^22
+29 ;;^UTILITY(U,$J,358.3,1139,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,1139,1,3,0)
+32 ;;=3^Atyp chronic myeloid leuk, BCR/ABL-neg, not achieve remis
+33 ;;^UTILITY(U,$J,358.3,1139,1,4,0)
+34 ;;=4^C92.20
+35 ;;^UTILITY(U,$J,358.3,1139,2)
+36 ;;=^5001795
+37 ;;^UTILITY(U,$J,358.3,1140,0)
+38 ;;=C92.21^^10^77^23
+39 ;;^UTILITY(U,$J,358.3,1140,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,1140,1,3,0)
+42 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
+43 ;;^UTILITY(U,$J,358.3,1140,1,4,0)
+44 ;;=4^C92.21
+45 ;;^UTILITY(U,$J,358.3,1140,2)
+46 ;;=^5001796
+47 ;;^UTILITY(U,$J,358.3,1141,0)
+48 ;;=C92.22^^10^77^24
+49 ;;^UTILITY(U,$J,358.3,1141,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,1141,1,3,0)
+52 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
+53 ;;^UTILITY(U,$J,358.3,1141,1,4,0)
+54 ;;=4^C92.22
+55 ;;^UTILITY(U,$J,358.3,1141,2)
+56 ;;=^5001797
+57 ;;^UTILITY(U,$J,358.3,1142,0)
+58 ;;=C92.30^^10^77^57
+59 ;;^UTILITY(U,$J,358.3,1142,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,1142,1,3,0)
+62 ;;=3^Myeloid sarcoma, not having achieved remission
+63 ;;^UTILITY(U,$J,358.3,1142,1,4,0)
+64 ;;=4^C92.30
+65 ;;^UTILITY(U,$J,358.3,1142,2)
+66 ;;=^5001798
+67 ;;^UTILITY(U,$J,358.3,1143,0)
+68 ;;=C92.31^^10^77^56
+69 ;;^UTILITY(U,$J,358.3,1143,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,1143,1,3,0)
+72 ;;=3^Myeloid sarcoma, in remission
+73 ;;^UTILITY(U,$J,358.3,1143,1,4,0)
+74 ;;=4^C92.31
+75 ;;^UTILITY(U,$J,358.3,1143,2)
+76 ;;=^5001799
+77 ;;^UTILITY(U,$J,358.3,1144,0)
+78 ;;=C92.32^^10^77^55
+79 ;;^UTILITY(U,$J,358.3,1144,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,1144,1,3,0)
+82 ;;=3^Myeloid sarcoma, in relapse
+83 ;;^UTILITY(U,$J,358.3,1144,1,4,0)
+84 ;;=4^C92.32
+85 ;;^UTILITY(U,$J,358.3,1144,2)
+86 ;;=^5001800
+87 ;;^UTILITY(U,$J,358.3,1145,0)
+88 ;;=C92.90^^10^77^54
+89 ;;^UTILITY(U,$J,358.3,1145,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,1145,1,3,0)
+92 ;;=3^Myeloid leukemia, unspecified, not having achieved remission
+93 ;;^UTILITY(U,$J,358.3,1145,1,4,0)
+94 ;;=4^C92.90
+95 ;;^UTILITY(U,$J,358.3,1145,2)
+96 ;;=^5001810
+97 ;;^UTILITY(U,$J,358.3,1146,0)
+98 ;;=C92.91^^10^77^53
+99 ;;^UTILITY(U,$J,358.3,1146,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,1146,1,3,0)
+102 ;;=3^Myeloid leukemia, unspecified in remission
+103 ;;^UTILITY(U,$J,358.3,1146,1,4,0)
+104 ;;=4^C92.91
+105 ;;^UTILITY(U,$J,358.3,1146,2)
+106 ;;=^5001811
+107 ;;^UTILITY(U,$J,358.3,1147,0)
+108 ;;=C92.92^^10^77^52
+109 ;;^UTILITY(U,$J,358.3,1147,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,1147,1,3,0)
+112 ;;=3^Myeloid leukemia, unspecified in relapse
+113 ;;^UTILITY(U,$J,358.3,1147,1,4,0)
+114 ;;=4^C92.92
+115 ;;^UTILITY(U,$J,358.3,1147,2)
+116 ;;=^5001812
+117 ;;^UTILITY(U,$J,358.3,1148,0)
+118 ;;=C93.00^^10^77^12
+119 ;;^UTILITY(U,$J,358.3,1148,1,0)
+120 ;;=^358.31IA^4^2
+121 ;;^UTILITY(U,$J,358.3,1148,1,3,0)
+122 ;;=3^Acute monoblastic/monocytic leukemia, not achieve remission
+123 ;;^UTILITY(U,$J,358.3,1148,1,4,0)
+124 ;;=4^C93.00
+125 ;;^UTILITY(U,$J,358.3,1148,2)
+126 ;;=^5001819
+127 ;;^UTILITY(U,$J,358.3,1149,0)
+128 ;;=C93.01^^10^77^10
+129 ;;^UTILITY(U,$J,358.3,1149,1,0)
+130 ;;=^358.31IA^4^2
+131 ;;^UTILITY(U,$J,358.3,1149,1,3,0)
+132 ;;=3^Acute monoblastic/monocytic leukemia, in remission
+133 ;;^UTILITY(U,$J,358.3,1149,1,4,0)
+134 ;;=4^C93.01
+135 ;;^UTILITY(U,$J,358.3,1149,2)
+136 ;;=^5001820
+137 ;;^UTILITY(U,$J,358.3,1150,0)
+138 ;;=C93.02^^10^77^11
+139 ;;^UTILITY(U,$J,358.3,1150,1,0)
+140 ;;=^358.31IA^4^2
+141 ;;^UTILITY(U,$J,358.3,1150,1,3,0)
+142 ;;=3^Acute monoblastic/monocytic leukemia, in relapse
+143 ;;^UTILITY(U,$J,358.3,1150,1,4,0)
+144 ;;=4^C93.02
+145 ;;^UTILITY(U,$J,358.3,1150,2)
+146 ;;=^5001821
+147 ;;^UTILITY(U,$J,358.3,1151,0)
+148 ;;=C93.10^^10^77^31
+149 ;;^UTILITY(U,$J,358.3,1151,1,0)
+150 ;;=^358.31IA^4^2
+151 ;;^UTILITY(U,$J,358.3,1151,1,3,0)
+152 ;;=3^Chronic myelomonocytic leukemia not achieve remission
+153 ;;^UTILITY(U,$J,358.3,1151,1,4,0)
+154 ;;=4^C93.10
+155 ;;^UTILITY(U,$J,358.3,1151,2)
+156 ;;=^5001822
+157 ;;^UTILITY(U,$J,358.3,1152,0)
+158 ;;=C93.11^^10^77^33
+159 ;;^UTILITY(U,$J,358.3,1152,1,0)
+160 ;;=^358.31IA^4^2
+161 ;;^UTILITY(U,$J,358.3,1152,1,3,0)
+162 ;;=3^Chronic myelomonocytic leukemia, in remission
+163 ;;^UTILITY(U,$J,358.3,1152,1,4,0)
+164 ;;=4^C93.11
+165 ;;^UTILITY(U,$J,358.3,1152,2)
+166 ;;=^5001823
+167 ;;^UTILITY(U,$J,358.3,1153,0)
+168 ;;=C93.12^^10^77^32
+169 ;;^UTILITY(U,$J,358.3,1153,1,0)
+170 ;;=^358.31IA^4^2
+171 ;;^UTILITY(U,$J,358.3,1153,1,3,0)
+172 ;;=3^Chronic myelomonocytic leukemia, in relapse
+173 ;;^UTILITY(U,$J,358.3,1153,1,4,0)
+174 ;;=4^C93.12
+175 ;;^UTILITY(U,$J,358.3,1153,2)
+176 ;;=^5001824
+177 ;;^UTILITY(U,$J,358.3,1154,0)
+178 ;;=C93.90^^10^77^48
+179 ;;^UTILITY(U,$J,358.3,1154,1,0)
+180 ;;=^358.31IA^4^2
+181 ;;^UTILITY(U,$J,358.3,1154,1,3,0)
+182 ;;=3^Monocytic leukemia, unsp, not having achieved remission
+183 ;;^UTILITY(U,$J,358.3,1154,1,4,0)
+184 ;;=4^C93.90
+185 ;;^UTILITY(U,$J,358.3,1154,2)
+186 ;;=^5001828
+187 ;;^UTILITY(U,$J,358.3,1155,0)
+188 ;;=C93.91^^10^77^50
+189 ;;^UTILITY(U,$J,358.3,1155,1,0)
+190 ;;=^358.31IA^4^2
+191 ;;^UTILITY(U,$J,358.3,1155,1,3,0)
+192 ;;=3^Monocytic leukemia, unspecified in remission
+193 ;;^UTILITY(U,$J,358.3,1155,1,4,0)
+194 ;;=4^C93.91
+195 ;;^UTILITY(U,$J,358.3,1155,2)
+196 ;;=^5001829
+197 ;;^UTILITY(U,$J,358.3,1156,0)
+198 ;;=C93.92^^10^77^49
+199 ;;^UTILITY(U,$J,358.3,1156,1,0)
+200 ;;=^358.31IA^4^2
+201 ;;^UTILITY(U,$J,358.3,1156,1,3,0)
+202 ;;=3^Monocytic leukemia, unspecified in relapse
+203 ;;^UTILITY(U,$J,358.3,1156,1,4,0)
+204 ;;=4^C93.92
+205 ;;^UTILITY(U,$J,358.3,1156,2)
+206 ;;=^5001830
+207 ;;^UTILITY(U,$J,358.3,1157,0)
+208 ;;=C94.00^^10^77^3
+209 ;;^UTILITY(U,$J,358.3,1157,1,0)
+210 ;;=^358.31IA^4^2
+211 ;;^UTILITY(U,$J,358.3,1157,1,3,0)
+212 ;;=3^Acute erythroid leukemia, not having achieved remission
+213 ;;^UTILITY(U,$J,358.3,1157,1,4,0)
+214 ;;=4^C94.00
+215 ;;^UTILITY(U,$J,358.3,1157,2)
+216 ;;=^5001834
+217 ;;^UTILITY(U,$J,358.3,1158,0)
+218 ;;=C94.01^^10^77^2
+219 ;;^UTILITY(U,$J,358.3,1158,1,0)
+220 ;;=^358.31IA^4^2
+221 ;;^UTILITY(U,$J,358.3,1158,1,3,0)
+222 ;;=3^Acute erythroid leukemia, in remission
+223 ;;^UTILITY(U,$J,358.3,1158,1,4,0)
+224 ;;=4^C94.01
+225 ;;^UTILITY(U,$J,358.3,1158,2)
+226 ;;=^5001835
+227 ;;^UTILITY(U,$J,358.3,1159,0)
+228 ;;=C94.02^^10^77^1
+229 ;;^UTILITY(U,$J,358.3,1159,1,0)
+230 ;;=^358.31IA^4^2
+231 ;;^UTILITY(U,$J,358.3,1159,1,3,0)
+232 ;;=3^Acute erythroid leukemia, in relapse
+233 ;;^UTILITY(U,$J,358.3,1159,1,4,0)
+234 ;;=4^C94.02
+235 ;;^UTILITY(U,$J,358.3,1159,2)
+236 ;;=^5001836
+237 ;;^UTILITY(U,$J,358.3,1160,0)
+238 ;;=C94.20^^10^77^7
+239 ;;^UTILITY(U,$J,358.3,1160,1,0)
+240 ;;=^358.31IA^4^2
+241 ;;^UTILITY(U,$J,358.3,1160,1,3,0)
+242 ;;=3^Acute megakaryoblastic leukemia not achieve remission
+243 ;;^UTILITY(U,$J,358.3,1160,1,4,0)
+244 ;;=4^C94.20
+245 ;;^UTILITY(U,$J,358.3,1160,2)
+246 ;;=^5001837
+247 ;;^UTILITY(U,$J,358.3,1161,0)
+248 ;;=C94.21^^10^77^9
+249 ;;^UTILITY(U,$J,358.3,1161,1,0)
+250 ;;=^358.31IA^4^2
+251 ;;^UTILITY(U,$J,358.3,1161,1,3,0)
+252 ;;=3^Acute megakaryoblastic leukemia, in remission
+253 ;;^UTILITY(U,$J,358.3,1161,1,4,0)
+254 ;;=4^C94.21
+255 ;;^UTILITY(U,$J,358.3,1161,2)
+256 ;;=^5001838
+257 ;;^UTILITY(U,$J,358.3,1162,0)
+258 ;;=C94.22^^10^77^8
+259 ;;^UTILITY(U,$J,358.3,1162,1,0)
+260 ;;=^358.31IA^4^2
+261 ;;^UTILITY(U,$J,358.3,1162,1,3,0)
+262 ;;=3^Acute megakaryoblastic leukemia, in relapse
+263 ;;^UTILITY(U,$J,358.3,1162,1,4,0)
+264 ;;=4^C94.22
+265 ;;^UTILITY(U,$J,358.3,1162,2)
+266 ;;=^5001839
+267 ;;^UTILITY(U,$J,358.3,1163,0)
+268 ;;=C94.30^^10^77^45
+269 ;;^UTILITY(U,$J,358.3,1163,1,0)
+270 ;;=^358.31IA^4^2
+271 ;;^UTILITY(U,$J,358.3,1163,1,3,0)
+272 ;;=3^Mast cell leukemia not having achieved remission
+273 ;;^UTILITY(U,$J,358.3,1163,1,4,0)
+274 ;;=4^C94.30
+275 ;;^UTILITY(U,$J,358.3,1163,2)
+276 ;;=^5001840
+277 ;;^UTILITY(U,$J,358.3,1164,0)
+278 ;;=C94.31^^10^77^47
+279 ;;^UTILITY(U,$J,358.3,1164,1,0)
+280 ;;=^358.31IA^4^2
+281 ;;^UTILITY(U,$J,358.3,1164,1,3,0)
+282 ;;=3^Mast cell leukemia, in remission
+283 ;;^UTILITY(U,$J,358.3,1164,1,4,0)
+284 ;;=4^C94.31
+285 ;;^UTILITY(U,$J,358.3,1164,2)
+286 ;;=^5001841
+287 ;;^UTILITY(U,$J,358.3,1165,0)
+288 ;;=C94.32^^10^77^46
+289 ;;^UTILITY(U,$J,358.3,1165,1,0)
+290 ;;=^358.31IA^4^2
+291 ;;^UTILITY(U,$J,358.3,1165,1,3,0)
+292 ;;=3^Mast cell leukemia, in relapse
+293 ;;^UTILITY(U,$J,358.3,1165,1,4,0)
+294 ;;=4^C94.32
+295 ;;^UTILITY(U,$J,358.3,1165,2)
+296 ;;=^5001842
+297 ;;^UTILITY(U,$J,358.3,1166,0)
+298 ;;=C95.00^^10^77^4
+299 ;;^UTILITY(U,$J,358.3,1166,1,0)
+300 ;;=^358.31IA^4^2
+301 ;;^UTILITY(U,$J,358.3,1166,1,3,0)
+302 ;;=3^Acute leukemia of unsp cell type not achieve remission
+303 ;;^UTILITY(U,$J,358.3,1166,1,4,0)
+304 ;;=4^C95.00
+305 ;;^UTILITY(U,$J,358.3,1166,2)
+306 ;;=^5001850
+307 ;;^UTILITY(U,$J,358.3,1167,0)
+308 ;;=C95.01^^10^77^5
+309 ;;^UTILITY(U,$J,358.3,1167,1,0)
+310 ;;=^358.31IA^4^2
+311 ;;^UTILITY(U,$J,358.3,1167,1,3,0)
+312 ;;=3^Acute leukemia of unspecified cell type, in remission
+313 ;;^UTILITY(U,$J,358.3,1167,1,4,0)
+314 ;;=4^C95.01
+315 ;;^UTILITY(U,$J,358.3,1167,2)
+316 ;;=^5001851
+317 ;;^UTILITY(U,$J,358.3,1168,0)
+318 ;;=C95.02^^10^77^6
+319 ;;^UTILITY(U,$J,358.3,1168,1,0)
+320 ;;=^358.31IA^4^2
+321 ;;^UTILITY(U,$J,358.3,1168,1,3,0)
+322 ;;=3^Acute leukemia of unspecified cell type, in relapse
+323 ;;^UTILITY(U,$J,358.3,1168,1,4,0)
+324 ;;=4^C95.02
+325 ;;^UTILITY(U,$J,358.3,1168,2)
+326 ;;=^5001852
+327 ;;^UTILITY(U,$J,358.3,1169,0)
+328 ;;=D45.^^10^77^58
+329 ;;^UTILITY(U,$J,358.3,1169,1,0)
+330 ;;=^358.31IA^4^2
+331 ;;^UTILITY(U,$J,358.3,1169,1,3,0)
+332 ;;=3^Polycythemia vera
+333 ;;^UTILITY(U,$J,358.3,1169,1,4,0)
+334 ;;=4^D45.
+335 ;;^UTILITY(U,$J,358.3,1169,2)
+336 ;;=^96105
+337 ;;^UTILITY(U,$J,358.3,1170,0)
+338 ;;=C95.10^^10^77^25
+339 ;;^UTILITY(U,$J,358.3,1170,1,0)
+340 ;;=^358.31IA^4^2
+341 ;;^UTILITY(U,$J,358.3,1170,1,3,0)
+342 ;;=3^Chronic leukemia of unsp cell type not achieve remission
+343 ;;^UTILITY(U,$J,358.3,1170,1,4,0)
+344 ;;=4^C95.10
+345 ;;^UTILITY(U,$J,358.3,1170,2)
+346 ;;=^5001853
+347 ;;^UTILITY(U,$J,358.3,1171,0)
+348 ;;=C95.11^^10^77^26
+349 ;;^UTILITY(U,$J,358.3,1171,1,0)
+350 ;;=^358.31IA^4^2
+351 ;;^UTILITY(U,$J,358.3,1171,1,3,0)
+352 ;;=3^Chronic leukemia of unspecified cell type, in remission
+353 ;;^UTILITY(U,$J,358.3,1171,1,4,0)
+354 ;;=4^C95.11
+355 ;;^UTILITY(U,$J,358.3,1171,2)
+356 ;;=^5001854
+357 ;;^UTILITY(U,$J,358.3,1172,0)
+358 ;;=C95.12^^10^77^27
+359 ;;^UTILITY(U,$J,358.3,1172,1,0)
+360 ;;=^358.31IA^4^2
+361 ;;^UTILITY(U,$J,358.3,1172,1,3,0)
+362 ;;=3^Chronic leukemia of unspecified cell type, in relapse
+363 ;;^UTILITY(U,$J,358.3,1172,1,4,0)
+364 ;;=4^C95.12
+365 ;;^UTILITY(U,$J,358.3,1172,2)
+366 ;;=^5001855
+367 ;;^UTILITY(U,$J,358.3,1173,0)
+368 ;;=D46.9^^10^77^51
+369 ;;^UTILITY(U,$J,358.3,1173,1,0)
+370 ;;=^358.31IA^4^2
+371 ;;^UTILITY(U,$J,358.3,1173,1,3,0)
+372 ;;=3^Myelodysplastic syndrome, unspecified
+373 ;;^UTILITY(U,$J,358.3,1173,1,4,0)
+374 ;;=4^D46.9
+375 ;;^UTILITY(U,$J,358.3,1173,2)
+376 ;;=^334031
+377 ;;^UTILITY(U,$J,358.3,1174,0)
+378 ;;=C95.90^^10^77^39
+379 ;;^UTILITY(U,$J,358.3,1174,1,0)
+380 ;;=^358.31IA^4^2
+381 ;;^UTILITY(U,$J,358.3,1174,1,3,0)
+382 ;;=3^Leukemia, unspecified not having achieved remission
+383 ;;^UTILITY(U,$J,358.3,1174,1,4,0)
+384 ;;=4^C95.90
+385 ;;^UTILITY(U,$J,358.3,1174,2)
+386 ;;=^5001856
+387 ;;^UTILITY(U,$J,358.3,1175,0)
+388 ;;=C95.91^^10^77^41
+389 ;;^UTILITY(U,$J,358.3,1175,1,0)
+390 ;;=^358.31IA^4^2
+391 ;;^UTILITY(U,$J,358.3,1175,1,3,0)
+392 ;;=3^Leukemia, unspecified, in remission
+393 ;;^UTILITY(U,$J,358.3,1175,1,4,0)
+394 ;;=4^C95.91
+395 ;;^UTILITY(U,$J,358.3,1175,2)
+396 ;;=^5001857
+397 ;;^UTILITY(U,$J,358.3,1176,0)
+398 ;;=C95.92^^10^77^40
+399 ;;^UTILITY(U,$J,358.3,1176,1,0)
+400 ;;=^358.31IA^4^2
+401 ;;^UTILITY(U,$J,358.3,1176,1,3,0)
+402 ;;=3^Leukemia, unspecified, in relapse
+403 ;;^UTILITY(U,$J,358.3,1176,1,4,0)
+404 ;;=4^C95.92
+405 ;;^UTILITY(U,$J,358.3,1176,2)
+406 ;;=^5001858
+407 ;;^UTILITY(U,$J,358.3,1177,0)
+408 ;;=D72.9^^10^77^35
+409 ;;^UTILITY(U,$J,358.3,1177,1,0)
+410 ;;=^358.31IA^4^2
+411 ;;^UTILITY(U,$J,358.3,1177,1,3,0)
+412 ;;=3^Disorder of white blood cells, unspecified
+413 ;;^UTILITY(U,$J,358.3,1177,1,4,0)
+414 ;;=4^D72.9
+415 ;;^UTILITY(U,$J,358.3,1177,2)
+416 ;;=^5002381
+417 ;;^UTILITY(U,$J,358.3,1178,0)
+418 ;;=D75.1^^10^77^59
+419 ;;^UTILITY(U,$J,358.3,1178,1,0)
+420 ;;=^358.31IA^4^2
+421 ;;^UTILITY(U,$J,358.3,1178,1,3,0)
+422 ;;=3^Secondary polycythemia
+423 ;;^UTILITY(U,$J,358.3,1178,1,4,0)
+424 ;;=4^D75.1
+425 ;;^UTILITY(U,$J,358.3,1178,2)
+426 ;;=^186856
+427 ;;^UTILITY(U,$J,358.3,1179,0)
+428 ;;=D75.9^^10^77^34
+429 ;;^UTILITY(U,$J,358.3,1179,1,0)
+430 ;;=^358.31IA^4^2
+431 ;;^UTILITY(U,$J,358.3,1179,1,3,0)
+432 ;;=3^Disease of blood and blood-forming organs, unspecified
+433 ;;^UTILITY(U,$J,358.3,1179,1,4,0)
+434 ;;=4^D75.9
+435 ;;^UTILITY(U,$J,358.3,1179,2)
+436 ;;=^5002393
+437 ;;^UTILITY(U,$J,358.3,1180,0)
+438 ;;=C7A.010^^10^77^42
+439 ;;^UTILITY(U,$J,358.3,1180,1,0)
+440 ;;=^358.31IA^4^2
+441 ;;^UTILITY(U,$J,358.3,1180,1,3,0)
+442 ;;=3^Malignant carcinoid tumor of the duodenum
+443 ;;^UTILITY(U,$J,358.3,1180,1,4,0)
+444 ;;=4^C7A.010
+445 ;;^UTILITY(U,$J,358.3,1180,2)
+446 ;;=^5001359
+447 ;;^UTILITY(U,$J,358.3,1181,0)
+448 ;;=C7A.011^^10^77^44
+449 ;;^UTILITY(U,$J,358.3,1181,1,0)
+450 ;;=^358.31IA^4^2
+451 ;;^UTILITY(U,$J,358.3,1181,1,3,0)
+452 ;;=3^Malignant carcinoid tumor of the jejunum
+453 ;;^UTILITY(U,$J,358.3,1181,1,4,0)
+454 ;;=4^C7A.011
+455 ;;^UTILITY(U,$J,358.3,1181,2)
+456 ;;=^5001360
+457 ;;^UTILITY(U,$J,358.3,1182,0)
+458 ;;=C7A.012^^10^77^43
+459 ;;^UTILITY(U,$J,358.3,1182,1,0)
+460 ;;=^358.31IA^4^2
+461 ;;^UTILITY(U,$J,358.3,1182,1,3,0)
+462 ;;=3^Malignant carcinoid tumor of the ileum
+463 ;;^UTILITY(U,$J,358.3,1182,1,4,0)
+464 ;;=4^C7A.012
+465 ;;^UTILITY(U,$J,358.3,1182,2)
+466 ;;=^5001361
+467 ;;^UTILITY(U,$J,358.3,1183,0)
+468 ;;=C93.30^^10^77^38
+469 ;;^UTILITY(U,$J,358.3,1183,1,0)
+470 ;;=^358.31IA^4^2
+471 ;;^UTILITY(U,$J,358.3,1183,1,3,0)
+472 ;;=3^Juvenile myelomonocytic leukemia,no remission
+473 ;;^UTILITY(U,$J,358.3,1183,1,4,0)
+474 ;;=4^C93.30
+475 ;;^UTILITY(U,$J,358.3,1183,2)
+476 ;;=^5001825
+477 ;;^UTILITY(U,$J,358.3,1184,0)
+478 ;;=C93.31^^10^77^37
+479 ;;^UTILITY(U,$J,358.3,1184,1,0)
+480 ;;=^358.31IA^4^2
+481 ;;^UTILITY(U,$J,358.3,1184,1,3,0)
+482 ;;=3^Juvenile myelomonocytic leukemia,in remission
+483 ;;^UTILITY(U,$J,358.3,1184,1,4,0)
+484 ;;=4^C93.31
+485 ;;^UTILITY(U,$J,358.3,1184,2)
+486 ;;=^5001826
+487 ;;^UTILITY(U,$J,358.3,1185,0)
+488 ;;=C93.32^^10^77^36
+489 ;;^UTILITY(U,$J,358.3,1185,1,0)
+490 ;;=^358.31IA^4^2
+491 ;;^UTILITY(U,$J,358.3,1185,1,3,0)
+492 ;;=3^Juvenile myelomonocytic leukemia,in relapse
+493 ;;^UTILITY(U,$J,358.3,1185,1,4,0)
+494 ;;=4^C93.32
+495 ;;^UTILITY(U,$J,358.3,1185,2)
+496 ;;=^5001827
+497 ;;^UTILITY(U,$J,358.3,1186,0)
+498 ;;=D48.0^^10^78^5
+499 ;;^UTILITY(U,$J,358.3,1186,1,0)
+500 ;;=^358.31IA^4^2
+501 ;;^UTILITY(U,$J,358.3,1186,1,3,0)
+502 ;;=3^Neoplasm of uncertain behavior of bone/artic cartl
+503 ;;^UTILITY(U,$J,358.3,1186,1,4,0)
+504 ;;=4^D48.0
+505 ;;^UTILITY(U,$J,358.3,1186,2)
+506 ;;=^81953
+507 ;;^UTILITY(U,$J,358.3,1187,0)
+508 ;;=D48.1^^10^78^6
+509 ;;^UTILITY(U,$J,358.3,1187,1,0)
+510 ;;=^358.31IA^4^2
+511 ;;^UTILITY(U,$J,358.3,1187,1,3,0)
+512 ;;=3^Neoplasm of uncertain behavior of connctv/soft tiss
+513 ;;^UTILITY(U,$J,358.3,1187,1,4,0)
+514 ;;=4^D48.1
+515 ;;^UTILITY(U,$J,358.3,1187,2)
+516 ;;=^267776
+517 ;;^UTILITY(U,$J,358.3,1188,0)
+518 ;;=D48.5^^10^78^10
+519 ;;^UTILITY(U,$J,358.3,1188,1,0)
+520 ;;=^358.31IA^4^2
+521 ;;^UTILITY(U,$J,358.3,1188,1,3,0)
+522 ;;=3^Neoplasm of uncertain behavior of skin
+523 ;;^UTILITY(U,$J,358.3,1188,1,4,0)
+524 ;;=4^D48.5
+525 ;;^UTILITY(U,$J,358.3,1188,2)
+526 ;;=^267777
+527 ;;^UTILITY(U,$J,358.3,1189,0)
+528 ;;=D48.61^^10^78^9
+529 ;;^UTILITY(U,$J,358.3,1189,1,0)
+530 ;;=^358.31IA^4^2
+531 ;;^UTILITY(U,$J,358.3,1189,1,3,0)
+532 ;;=3^Neoplasm of uncertain behavior of right breast
+533 ;;^UTILITY(U,$J,358.3,1189,1,4,0)
+534 ;;=4^D48.61
+535 ;;^UTILITY(U,$J,358.3,1189,2)
+536 ;;=^5002267
+537 ;;^UTILITY(U,$J,358.3,1190,0)
+538 ;;=D48.62^^10^78^7
+539 ;;^UTILITY(U,$J,358.3,1190,1,0)
+540 ;;=^358.31IA^4^2
+541 ;;^UTILITY(U,$J,358.3,1190,1,3,0)
+542 ;;=3^Neoplasm of uncertain behavior of left breast
+543 ;;^UTILITY(U,$J,358.3,1190,1,4,0)
+544 ;;=4^D48.62
+545 ;;^UTILITY(U,$J,358.3,1190,2)
+546 ;;=^5002268
+547 ;;^UTILITY(U,$J,358.3,1191,0)
+548 ;;=D46.0^^10^78^18
+549 ;;^UTILITY(U,$J,358.3,1191,1,0)
+550 ;;=^358.31IA^4^2
+551 ;;^UTILITY(U,$J,358.3,1191,1,3,0)
+552 ;;=3^Refractory anemia without ring sideroblasts, so stated
+553 ;;^UTILITY(U,$J,358.3,1191,1,4,0)
+554 ;;=4^D46.0
+555 ;;^UTILITY(U,$J,358.3,1191,2)
+556 ;;=^5002245
+557 ;;^UTILITY(U,$J,358.3,1192,0)
+558 ;;=D46.1^^10^78^17
+559 ;;^UTILITY(U,$J,358.3,1192,1,0)
+560 ;;=^358.31IA^4^2
+561 ;;^UTILITY(U,$J,358.3,1192,1,3,0)
+562 ;;=3^Refractory anemia with ring sideroblasts
+563 ;;^UTILITY(U,$J,358.3,1192,1,4,0)
+564 ;;=4^D46.1
+565 ;;^UTILITY(U,$J,358.3,1192,2)
+566 ;;=^5002246
+567 ;;^UTILITY(U,$J,358.3,1193,0)
+568 ;;=D46.20^^10^78^14
+569 ;;^UTILITY(U,$J,358.3,1193,1,0)
+570 ;;=^358.31IA^4^2
+571 ;;^UTILITY(U,$J,358.3,1193,1,3,0)
+572 ;;=3^Refractory anemia with excess of blasts, unspecified
+573 ;;^UTILITY(U,$J,358.3,1193,1,4,0)
+574 ;;=4^D46.20
+575 ;;^UTILITY(U,$J,358.3,1193,2)
+576 ;;=^5002247
+577 ;;^UTILITY(U,$J,358.3,1194,0)
+578 ;;=D46.21^^10^78^15
+579 ;;^UTILITY(U,$J,358.3,1194,1,0)
+580 ;;=^358.31IA^4^2
+581 ;;^UTILITY(U,$J,358.3,1194,1,3,0)
+582 ;;=3^Refractory anemia with excess of blasts 1
+583 ;;^UTILITY(U,$J,358.3,1194,1,4,0)
+584 ;;=4^D46.21
+585 ;;^UTILITY(U,$J,358.3,1194,2)
+586 ;;=^5002248
+587 ;;^UTILITY(U,$J,358.3,1195,0)
+588 ;;=D46.A^^10^78^19
+589 ;;^UTILITY(U,$J,358.3,1195,1,0)
+590 ;;=^358.31IA^4^2
+591 ;;^UTILITY(U,$J,358.3,1195,1,3,0)
+592 ;;=3^Refractory cytopenia with multilineage dysplasia
+593 ;;^UTILITY(U,$J,358.3,1195,1,4,0)
+594 ;;=4^D46.A
+595 ;;^UTILITY(U,$J,358.3,1195,2)
+596 ;;=^5002251
+597 ;;^UTILITY(U,$J,358.3,1196,0)
+598 ;;=D46.B^^10^78^13
+599 ;;^UTILITY(U,$J,358.3,1196,1,0)
+600 ;;=^358.31IA^4^2
+601 ;;^UTILITY(U,$J,358.3,1196,1,3,0)
+602 ;;=3^Refract cytopenia w multilin dysplasia and ring sideroblasts
+603 ;;^UTILITY(U,$J,358.3,1196,1,4,0)
+604 ;;=4^D46.B
+605 ;;^UTILITY(U,$J,358.3,1196,2)
+606 ;;=^5002252
+607 ;;^UTILITY(U,$J,358.3,1197,0)
+608 ;;=D46.22^^10^78^16
+609 ;;^UTILITY(U,$J,358.3,1197,1,0)
+610 ;;=^358.31IA^4^2
+611 ;;^UTILITY(U,$J,358.3,1197,1,3,0)
+612 ;;=3^Refractory anemia with excess of blasts 2
+613 ;;^UTILITY(U,$J,358.3,1197,1,4,0)
+614 ;;=4^D46.22
+615 ;;^UTILITY(U,$J,358.3,1197,2)
+616 ;;=^5002249
+617 ;;^UTILITY(U,$J,358.3,1198,0)
+618 ;;=D46.C^^10^78^3
+619 ;;^UTILITY(U,$J,358.3,1198,1,0)
+620 ;;=^358.31IA^4^2
+621 ;;^UTILITY(U,$J,358.3,1198,1,3,0)
+622 ;;=3^Myelodysplastic syndrome w isolated del(5q) chromsoml abnlt
+623 ;;^UTILITY(U,$J,358.3,1198,1,4,0)
+624 ;;=4^D46.C
+625 ;;^UTILITY(U,$J,358.3,1198,2)
+626 ;;=^5002253
+627 ;;^UTILITY(U,$J,358.3,1199,0)
+628 ;;=D46.9^^10^78^4
+629 ;;^UTILITY(U,$J,358.3,1199,1,0)
+630 ;;=^358.31IA^4^2
+631 ;;^UTILITY(U,$J,358.3,1199,1,3,0)
+632 ;;=3^Myelodysplastic syndrome, unspecified
+633 ;;^UTILITY(U,$J,358.3,1199,1,4,0)
+634 ;;=4^D46.9
+635 ;;^UTILITY(U,$J,358.3,1199,2)
+636 ;;=^334031
+637 ;;^UTILITY(U,$J,358.3,1200,0)
+638 ;;=D47.1^^10^78^1
+639 ;;^UTILITY(U,$J,358.3,1200,1,0)
+640 ;;=^358.31IA^4^2
+641 ;;^UTILITY(U,$J,358.3,1200,1,3,0)
+642 ;;=3^Chronic myeloproliferative disease
+643 ;;^UTILITY(U,$J,358.3,1200,1,4,0)
+644 ;;=4^D47.1
+645 ;;^UTILITY(U,$J,358.3,1200,2)
+646 ;;=^5002256
+647 ;;^UTILITY(U,$J,358.3,1201,0)
+648 ;;=D47.Z1^^10^78^12
+649 ;;^UTILITY(U,$J,358.3,1201,1,0)
+650 ;;=^358.31IA^4^2
+651 ;;^UTILITY(U,$J,358.3,1201,1,3,0)
+652 ;;=3^Post-transplant lymphoproliferative disorder (PTLD)
+653 ;;^UTILITY(U,$J,358.3,1201,1,4,0)
+654 ;;=4^D47.Z1
+655 ;;^UTILITY(U,$J,358.3,1201,2)
+656 ;;=^5002261
+657 ;;^UTILITY(U,$J,358.3,1202,0)
+658 ;;=D48.7^^10^78^8
+659 ;;^UTILITY(U,$J,358.3,1202,1,0)
+660 ;;=^358.31IA^4^2
+661 ;;^UTILITY(U,$J,358.3,1202,1,3,0)
+662 ;;=3^Neoplasm of uncertain behavior of other specified sites
+663 ;;^UTILITY(U,$J,358.3,1202,1,4,0)
+664 ;;=4^D48.7
+665 ;;^UTILITY(U,$J,358.3,1202,2)
+666 ;;=^267779
+667 ;;^UTILITY(U,$J,358.3,1203,0)
+668 ;;=D48.9^^10^78^11
